Pharmacotherapy of metastatic melanoma: Emerging trends and opportunities for a cure
Authors:
- 24 May 2013
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 139 (3) , 405-411
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- Impact of albumin on drug delivery — New applications on the horizonJournal of Controlled Release, 2012
- A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic MelanomaClinical Cancer Research, 2011
- Mechanisms of Resistance to RAF Inhibitors in MelanomaJournal of Investigative Dermatology, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- 124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Mutations of the BRAF gene in human cancerNature, 2002